Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review - Test2 - elhamkhani - TriplyDB

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

http://www.wikidata.org/entity/Q26850912

about

Repurposing metformin: an old drug with new tricks in its binding pockets Repurposing metformin for cancer treatment: current clinical studies Obesity and cancer: mechanistic insights from transdisciplinary studies Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells Mitohormesis Old drug, new trick: repurposing metformin for gynecologic cancers?Hyperglycemia as a risk factor for cancer progression Heterogeneity of glycolysis in cancers and therapeutic opportunities.Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment Nutrition, dietary interventions and prostate cancer: the latest evidence Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies Metformin Prevents Cisplatin-Induced Cognitive Impairment and Brain Damage in Mice MATE2 Expression Is Associated with Cancer Cell Response to Metformin 2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications Using EHR-Linked Biobank Data to Study Metformin Pharmacogenomics.Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma.CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes.Metformin and the risk of cancer in type 2 diabetes: methodological challenges and perspectives Metformin in cancer prevention and therapy.The role of obesity in oesophageal cancer development.Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium.Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma The diabetes-cancer link Risk factors for pancreatic cancer: a summary review of meta-analytical studies.Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study Metformin impairs Rho GTPase signaling to induce apoptosis in neuroblastoma cells and inhibits growth of tumors in the xenograft mouse model of neuroblastoma.Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case-control study.Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma.Survival of patients with stage IV lung cancer with diabetes treated with metformin.Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis.Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes.

P2860

Q22250976-B60A1E97-450B-4502-B891-813376805D19 Q26752651-1516E1A6-D75F-4074-A7F5-48FD6B722118 Q26786829-7A46CE5F-5FDC-4124-A2B7-A22CCF8C588F Q26795625-DBDCFFC3-5607-4C28-8906-F2A2D02CB61B Q26827387-6ABC7B41-41B1-4CB4-990A-988356859CE5 Q26862860-A9FC6C09-4833-43AE-845F-62E9C3DB3808 Q27010558-4897E2E3-B1E0-45D9-947D-B3858D050E94 Q27687614-916E9664-35E7-4167-94AA-5F0AC97CD489 Q27693375-52FA5D4C-D519-4220-8F15-A9C1BA2A9D54 Q28069605-221D9469-59AB-406E-9851-37F3BD1E1A26 Q28081491-04A698E5-5F4D-4AD8-BC48-ADC411DB2D6D Q28081657-2CC662A6-13CE-49F6-B36D-942D54711455 Q28084566-07290AD5-1DEE-4D72-A8CF-73683889E6B9 Q28084927-635FC59E-02A8-4E70-88C9-1C46F3B8F8CB Q28539104-F36A4D7D-16EE-4D46-8925-975F44999621 Q28542914-EA538E2B-9C4A-4F9D-8A57-5B9831BED209 Q28551025-73E11805-FA33-4B3D-809C-68F9DC00F105 Q28555000-7BB8B57D-94F0-4BFA-B607-11F04902B70F Q30239808-90DC1CD6-133C-4CD6-B666-43F719218030 Q30955177-2030E426-7C95-4E7F-A0E9-AE983673C6A6 Q33645356-896FE119-64F1-40C9-8D46-F9F667D4D038 Q33675285-C69CA25A-6B10-4F01-BA02-0964EB9756A6 Q33829461-8F7BD646-5303-48C4-8066-2CB14559C1B0 Q34135248-21E53DE7-4794-43D6-9FBD-3EA7103D1959 Q34323510-4B6AB8B9-5164-4A70-9598-36645BEA2ED1 Q34357944-2B07034B-51B6-4992-A9A9-D615786749CB Q34357983-33E83AA8-71D9-4E63-BDEE-EAAF13653DC7 Q34418740-6DF0288C-540C-47A9-8950-3E3FA5D81867 Q34505650-9B1D08DB-AD05-404B-A2DC-924D254F2AA7 Q34508880-DAD55729-19E6-4EFC-A62A-481D09B145CD Q34510892-1CFE53C2-C7FC-4441-BF63-A01D14D53F05 Q34667061-8910BC7D-354B-4E29-8D12-D73EBB1D7C56 Q34899291-379655CC-2288-4CA6-99F4-533772239B18 Q34957038-1C33D51E-A329-4EF3-B46C-CB7A0A092208 Q34998627-E035B714-43F3-4230-AE90-7235A02CC591 Q35084900-8456BF74-3CCD-4B50-A554-DAFF0EFB741F Q35115554-9BED1B86-0F70-4171-A693-6F1A8F098845 Q35153493-47045AC5-665C-4AED-8C0C-B0F5293D39CB Q35558619-23516606-333A-4B82-8C1E-37A28ADA687C Q35678036-B7A4AFD4-A882-4DA0-B700-4A2B2041CCCC

P2860

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

http://www.wikidata.org/entity/Q26850912

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

@ast

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

@en

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

@nl

type

label

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

@ast

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

@en

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

@nl

prefLabel

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

@ast

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

@en

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

@nl

P1433

Q26850912-27A655E2-D1BB-4559-AE97-ED9666EAA440

P1476

Q26850912-866A22FD-F455-469D-85D8-07423C64EE91

P2093

Q26850912-1DA5F78D-318A-4754-998F-3B07501DBB0D

Q26850912-3FB31958-1C75-4C19-99DF-C0CD94A0E55D

Q26850912-40370A4D-13E0-4435-8605-2B24F40C2414

Q26850912-4BEE39BC-A4FE-483B-8D8F-9E9810129E6C

Q26850912-A5EC37E0-DF34-463F-AEF3-C76D670ABA33

P275

Q26850912-2A62247C-D86B-459C-AD9F-46DC26EC4E54

P2860

Q26850912-06460E72-1CC7-4175-90D3-A889D40D1DBF

Q26850912-0A99DFB2-99C0-4B35-9695-C9E57EF27F2D

Q26850912-141E1331-10DB-4D32-AB38-BE296488CE77

Q26850912-16B7A4CC-3AF8-40C4-9F1C-59ABB54B8043

Q26850912-16BC84BE-F8F7-4A6A-9520-E081EE17EB5F

Q26850912-1D23A792-210B-48FA-8AF2-4D5D53972664

Q26850912-1FED4073-0934-4D33-9F63-7DF195091A89

Q26850912-229C60DF-8896-4A20-9D0E-25172772313C

Q26850912-278CC09D-9445-4C4E-8B7A-FF2E72D716C4

Q26850912-2BC5ADB5-4392-413C-8504-F6BEF51A5635

P304

Q26850912-DC5C0F59-09C8-43F9-B670-6A90981B0CD0

P31

Q26850912-0B15C14A-29F2-4348-994D-24B7AFB50686

Q26850912-1F5D0EE9-A4C2-4D79-89F5-11B0FAFA300F

Q26850912-305413BF-1C57-4399-82BA-B9B294C6D5DF

P3181

Q26850912-35E243BE-4B93-4723-8843-8C46121C3DE6

P356

Q26850912-4F43DA55-FBC7-4758-93A7-44C2539B0E44

P407

Q26850912-7BABA5A6-0B2D-49A6-8FE2-0B3E0C6DA652

P433

Q26850912-63A82BFE-5729-4E00-8D39-2FA66733DA10

P478

Q26850912-ED4F2BBD-FF81-4179-918F-64C5AE507059

P50

Q26850912-B41D265E-A255-4964-AF62-A88846419858

P5008

Q26850912-56D49AC4-6B3F-4336-8014-F6A4D1DD2422

P577

Q26850912-64495DE8-41AB-401B-8A86-15E1F4AA1505

Q26850912-96E00E0D-46D1-4F6F-A58B-82CFD2C31798

P5875

Q26850912-86077F82-7154-44A4-B26F-D2F60604F016

P698

Q26850912-66A79C4E-E59D-4BE9-9017-08CC39FFC491

P921

Q26850912-05802A77-52E7-4269-B33A-194DB08452CD

Q26850912-169D82ED-B705-4B1F-87B3-C682E2C6FC5C

Q26850912-21A6A5D9-115C-4122-B334-3B002338A3D0

Q26850912-40E997CB-0D7B-402C-8544-9EF8B9194F18

Q26850912-B479CA8A-9F30-4EFE-8EE4-2BD6A917B885

Q26850912-D764013C-F0A8-4C99-9F46-322A930F2663

P932

Q26850912-E5CB466B-10B8-4C2F-9825-9B6B32363358

P3181

P356

JOURNAL.PONE.0071583

P1433

P1476

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

@en

P2093

Emanuela Lapice

http://www.w3.org/2001/XMLSchema#string

Fabio Pellegrini

http://www.w3.org/2001/XMLSchema#string

Giovanni F. M. Strippoli

http://www.w3.org/2001/XMLSchema#string

Giuseppe Lucisano

http://www.w3.org/2001/XMLSchema#string

Monica Franciosi

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Role of AMP-activated protein kinase in mechanism of metformin action

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Measuring inconsistency in meta-analyses

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Metformin and reduced risk of cancer in diabetic patients

Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System

Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women.

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

P304

e71583

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

P3181

829397

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0071583

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Nicolucci

P5008

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2013-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255737401

http://www.w3.org/2001/XMLSchema#string

P698

23936520

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

complications of diabetes mellitus

maturity-onset diabetes of the young

P932

3732236

http://www.w3.org/2001/XMLSchema#string